Opinion

Video

Cyclosporine Ophthalmic Solution for Inflammatory Dry Eye

Author(s):

Alice Epitropoulos, MD,Laura M. Periman, MD

Dry eye experts discuss Cyclosporine ophthalmic solution.

Video content above is prompted by the following question(s):

1. Cyclosporine ophthalmic solution, 0.1% (VEVYE)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
Related Content
Surgical innovation in dry eye disease: Salivary gland transplant
September 2nd 2025

Surgical innovation in dry eye disease: Salivary gland transplant

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 2nd 2025

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye
September 2nd 2025

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 2nd 2025

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Raytone Biotech treats first patient in clinical trial of RTP-008 for dry eye disease
September 2nd 2025

Raytone Biotech treats first patient in clinical trial of RTP-008 for dry eye disease

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap
September 2nd 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap

© 2025 MJH Life Sciences

All rights reserved.